{
  "id": 8306254,
  "title": "Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs",
  "url": "https://urgent.news/2026/09/18/teva-highlights-new-real-world-data-showing-uzedy-risperidone",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T20:32:22.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/teva-highlights-new-real-world-data-showing-uzedy-risperidone-outperforms-other-long-acting-injectables-in-keeping-schizophrenia-patients-on-treatment-while-reducing-emergency-care-and-health"
  },
  "original_language": "en",
  "account": null,
  "summary": "New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I) The new real-world data also show that UZEDY decreased emergency room visits and hospitalizations, lowering overall healthcare resource utilization and delivering over $1,000 per patient per month in direct cost […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}